Purpose

The Pharmaceutical Society of Australia (PSA) makes this submission to the Australian Health Practitioner Regulation Agency on the draft guideline on Informing a National Board about where you practise. Comments provided by PSA in this submission relate to issues raised by registered pharmacists.

About PSA

PSA is the peak national professional pharmacy organisation representing Australia’s 31,000 pharmacists working in all sectors and locations.

PSA’s core functions include:

• providing high quality continuing professional development, education and practice support to pharmacists

• developing and advocating standards and guidelines to inform and enhance pharmacists’ practice

• representing pharmacists’ role as frontline health professionals.

PSA is also a registered training organisation and offers qualifications including certificate and diploma-level courses tailored for pharmacists, pharmacy assistants and interns.

---


Comments on the draft guideline

PSA understands the proposed guideline relates to the legislative amendments expected to commence in mid-2018 where a registered health practitioner will have an obligation to provide ‘practice information’ when requested by their National Board.

Overall, PSA supports the draft guideline in providing information about the health practitioner’s obligations based on relevant practice arrangements and the types of information that must be provided.

PSA provides the following feedback and suggestions (presented in the table) based on issues which were raised by PSA’s member pharmacists, for consideration by the Pharmacy Board. We believe that inclusion or clarification of these points will help ensure the Pharmacy Board’s statutory guideline adequately supports all pharmacists.

<table>
<thead>
<tr>
<th>Issue</th>
<th>PSA’s query / comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Applicability of the guideline</td>
<td>• The consultation paper outlines (on p. 2) who the guideline is relevant to or intended for. This information was not evident in the draft guideline section of the paper. Generally, guidelines issued by the Pharmacy Board contain a section headed “Who needs to use these guidelines?” and therefore, PSA suggests inclusion of a similar section.</td>
</tr>
<tr>
<td></td>
<td>• A query has been raised as to whether the guideline would apply to pharmacy students undertaking clinical placements. If so, would the student be considered to be providing services in a voluntary capacity or is there a contract or agreement between the university and the preceptor?</td>
</tr>
<tr>
<td>Conducting Home Medicines Reviews (HMRs)</td>
<td>Most pharmacists indicated that the explanation of different practice arrangements was useful and appropriate. However, PSA did receive several queries from pharmacists who regularly conduct HMRs. The following is an excerpt of the advice PSA provided internally during its consultation process based on its reading of the consultation paper.</td>
</tr>
<tr>
<td></td>
<td>• It is important to remember that your practice (business) “arrangement” (rather than your role or scope of practice) determines what information needs to be submitted when requested. For a pharmacist regularly conducting HMRs, you may be a self-employed practitioner (i.e. you own and manage your business) or you may have a contract or agreement with, for example, a community pharmacy. If both business arrangements apply, you would need to report practice information relevant to both when requested by the Pharmacy Board.</td>
</tr>
<tr>
<td></td>
<td>• If you are self-employed, do not share premises and write HMR reports at home, your home is your place of practice.</td>
</tr>
</tbody>
</table>
The names of other health practitioners are required to be reported when you share premises (including the cost of the premises) with those practitioners.

You are **not** required to provide residential addresses of any patients where health services were provided (e.g. through a home visit).

PSA would welcome feedback from the Pharmacy Board if the interpretation of the draft guideline, and therefore the internal advice given as outlined above, is incorrect.

Although we understand the draft guideline already captures most of the key pieces of information referred to above, it is clear to PSA that additional advice or reinforcement of information, particularly in the context of pharmacists undertaking HMRs, is desirable. PSA believes this would enhance the guideline overall for pharmacists.

If it is not appropriate to repeat similar information in this manner in the guideline, PSA would be pleased to work with the Pharmacy Board to issue advice to PSA members on these points.

### Appendix A

| The quick reference summary is a useful tool and should be retained. Some pharmacists felt that pharmacist-specific examples could be added to the current examples in the table to provide a clearer understanding. |
| Assistance with implementation of the guideline | As the peak professional body for pharmacists, PSA would be pleased to assist the Pharmacy Board by disseminating information and reinforcing key messages to pharmacists in relation to the implementation of the guideline. |

PSA would be pleased to clarify or discuss any information contained in this submission.

**Submitted by:**

Pharmaceutical Society of Australia  
PO Box 42  
Deakin West  ACT 2600  
Tel: 02 6283 4777  
[www.psa.org.au](http://www.psa.org.au)